When Myeloma Responds but Symptoms Remain: Closing the Quality-of-Life Gap

Positive lab results are often welcome news. For a patient with multiple myeloma who still struggles to get through the afternoon, however, it may not feel like the whole story. Treatment can move in the right direction while daily life remains difficult. Quality-of-life assessment deserves attention alongside disease response.¹

For pharmacists, that gap creates an opportunity to ask more specific questions. Rather than stopping at whether a patient is tolerating treatment, conversations can explore what symptoms prevent them from doing—and whether supportive care is keeping pace with their needs.¹

A Treatment Response Does Not Describe the Entire Experience

An exploratory secondary analysis of BMT CTN 0702 (NCT01109004) examined symptoms among patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. At baseline, 712 patients completed the questionnaire; follow-up assessments extended through 4 years after transplantation. Investigators identified persistent symptom clusters involving malaise, physical concerns, and emotional symptoms.²

The malaise and emotional clusters had a greater impact on quality of life than the physical symptom cluster. Baseline disease characteristics, including pretransplant response status, did not distinguish patients between higher and lower symptom burden. These findings support assessing symptoms directly rather than assuming that treatment response predicts how someone feels.²

The analysis was exploratory, and fewer patients completed later assessments. It does not establish how frequently symptoms persist with every contemporary regimen. Its practical message is nevertheless useful: a favorable disease assessment should leave room for a separate conversation about function and well-being.²

Make the Symptom Conversation Specific

Patient-reported symptoms also carry clinical information. In a real-world study published in Blood Advances, investigators evaluated a brief screen addressing fatigue, pain, and overall quality of life in newly diagnosed multiple myeloma. Fatigue and impaired quality of life were independently associated with shorter overall survival after adjustment for selected clinical factors.³

That association does not prove that treating fatigue improves survival. Instead, it does show why symptoms deserve documentation and follow-up rather than being treated as background noise.³

A pharmacy encounter can translate that principle into concrete questions: Has fatigue changed since the last cycle? Does pain interrupt sleep? Is numbness making it difficult to button a shirt? Recording the impact on an ordinary activity gives the care team a clearer target for reassessment.¹^,³

Treat Fatigue as a Symptom to Evaluate

Persistent fatigue warrants evaluation for contributing conditions and medication adverse effects. The American Society of Clinical Oncology (ASCO)–Society for Integrative Oncology fatigue guideline emphasizes assessment of factors such as anemia and sleep disturbance, alongside other contributors. Pharmacists can help identify medications that warrant review and communicate concerns to the oncology team.⁴

Management should extend beyond suggesting more rest. The guideline recommends exercise, cognitive behavioral therapy, and mindfulness-based programs during cancer treatment and after treatment completion. These recommendations draw on broader cancer populations, so their application to myeloma requires individual assessment.⁴

For a patient whose fatigue limits activity, a practical pharmacy contribution is helping arrange an appropriate referral and checking whether it occurred. Exercise recommendations should account for the patient’s clinical condition and treatment-related limitations. The guideline also advises against routinely recommending psychostimulants for cancer-related fatigue.⁴

Match Neuropathy Management to the Symptom

Neuropathy requires its own discussion. Painful tingling and loss of sensation can affect patients differently; asking about interference with daily activities helps clarify the problem. ASCO guidance recommends considering treatment modifications when chemotherapy-induced neuropathy becomes intolerable or causes functional impairment. Those decisions belong with the treating team.⁵

For established painful chemotherapy-induced peripheral neuropathy, duloxetine is the only agent with appropriate supporting evidence in the ASCO guideline, although the expected benefit is limited. That recommendation should not be generalized to every cause of neuropathy or to numbness without pain.⁵

Pharmacists can assess whether a proposed intervention fits the symptom and review the medication profile before recommending a change. Follow-up should establish whether the patient experiences a meaningful benefit.⁵

Give Symptom Improvement a Follow-Up Plan

A symptom discussion becomes useful when it produces a next step. Documenting the concern, identifying who will address it, and returning to the same functional question at a later encounter can make supportive care more deliberate.¹

For someone whose myeloma is responding, being able to finish a grocery trip may be an important measure of progress. Making room for that goal helps pharmacists connect treatment success with the life the patient is trying to regain.¹

REFERENCES

1. Brazauskas R, Flynn K, Krishnan A, et al. Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial. Br J Haematol. 2024;204(4):1429-1438. doi:10.1111/bjh.19326

2. Abdallah N, Bohra A, Mammadzadeh A, et al. Prognostic impact of patient-reported symptoms in multiple myeloma. Blood Adv. 2025;9(4):884-892. doi:10.1182/bloodadvances.2024014232

3. Bower JE, Lacchetti C, Alici Y, et al. Management of Fatigue in Adult Survivors of Cancer: ASCO-Society for Integrative Oncology Guideline Update. J Clin Oncol. 2024;42(20):2456-2487. doi:10.1200/JCO.24.00541doi:[10.1200/JCO.24.00541](https://doi.org/10.1200/JCO.24.00541)

4. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399

5. Banerjee R, Cheung MC, Derman B, et al. Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1. J Clin Oncol. 2026;44(22):e113-e124. doi:10.1200/JCO-26-01139